Ozempic and Gastroparesis: What Patients Should Know About Delayed Gastric Emptying
Latest update (2026-01)
FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]
From General Health Education to Targeted Safety Surveillance
If you or a loved one has been taking Ozempic and is experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering about the risk of gastroparesis—a condition where the stomach empties too slowly. The medical community has long recognized that certain medications can affect gastrointestinal motility, and the emergence of GLP-1 receptor agonists like Ozempic has brought renewed attention to this safety concern. This page reviews the FDA's adverse event reports, the evidence linking Ozempic to gastroparesis, and what patients need to know about monitoring and managing this potential side effect.
Bridging General Awareness to Specific Risk: The Ozempic-Gastroparesis Link
Building on the foundational understanding of medication safety, the specific relationship between Ozempic (semaglutide) and gastroparesis warrants detailed examination. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules, and management focuses on dietary modifications, prokinetic agents, and antiemetics. Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes, works by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. This pharmacological effect on gastric motility is central to its therapeutic action but also raises mechanistic concerns about potential causation of gastroparesis. Evidence from clinical trials indicates that gastrointestinal adverse reactions are significantly more common with Ozempic than placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and diarrhea occurred during dose escalation, and discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients (3.1% for 0.5 mg and 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Mechanistic Evidence and Clinical Trial Data
In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% and 34.0% of patients, respectively (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients include nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data highlight a dose-dependent increase in gastrointestinal symptoms, which are consistent with the known effects of GLP-1 agonists on gastric emptying. Mechanistically, Ozempic delays gastric emptying by activating GLP-1 receptors on enteric neurons and smooth muscle, reducing antral contractions and increasing pyloric tone. This pharmacodynamic effect is intended to improve postprandial glycemic control but can lead to prolonged gastric retention. In susceptible individuals, this may progress to symptomatic gastroparesis, particularly if the drug is continued despite persistent symptoms.
FDA Warning and Risk Communication Gaps
The FDA prescribing information for Ozempic lists pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury, hypersensitivity, and acute gallbladder disease as serious adverse reactions, but does not explicitly list gastroparesis as a separate warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the common gastrointestinal adverse reactions—nausea, vomiting, abdominal pain, and constipation—overlap with gastroparesis symptoms, and the drug’s effect on gastric motility is well-documented. Regarding risk communication, the adequacy of warnings about Ozempic and gastroparesis is a key concern. The prescribing information includes gastrointestinal adverse reactions in a table and notes that most events occurred during dose escalation, but it does not provide specific guidance on monitoring for gastroparesis or criteria for discontinuation beyond general intolerance. For affected patients, causation considerations involve the temporal relationship between Ozempic initiation and symptom onset, exclusion of other causes (e.g., diabetic gastroparesis, postsurgical changes, or idiopathic disease), and the potential for symptom resolution upon drug cessation. The timeline between exposure and documented harm is variable; gastrointestinal symptoms often emerge during dose escalation, but gastroparesis may develop insidiously over weeks to months. In clinical trials, the majority of nausea, vomiting, and diarrhea occurred during dose escalation, suggesting an early effect, but persistent symptoms may indicate a more sustained impact on gastric motility (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Causation Assessment and Clinical Implications
In summary, while Ozempic is not explicitly labeled as causing gastroparesis, its pharmacological mechanism and the high incidence of gastrointestinal adverse reactions support a plausible link. Patients experiencing persistent nausea, vomiting, or abdominal pain should be evaluated for gastroparesis, and clinicians should consider dose reduction or discontinuation. The FDA warning does not currently include gastroparesis as a distinct risk, but the evidence from clinical trials underscores the need for vigilance. Further research is warranted to clarify the incidence of gastroparesis in Ozempic users and to optimize risk mitigation strategies. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the FDA warning regarding Ozempic and gastroparesis?
The FDA prescribing information for Ozempic does not explicitly list gastroparesis as a separate warning, but it includes gastrointestinal adverse reactions such as nausea, vomiting, abdominal pain, and constipation, which overlap with gastroparesis symptoms. The drug's effect on gastric motility is well-documented, and the FDA notes that most gastrointestinal events occur during dose escalation. However, there is no specific guidance on monitoring for gastroparesis or criteria for discontinuation beyond general intolerance.
How does Ozempic cause gastroparesis?
Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying by activating receptors on enteric neurons and smooth muscle, reducing antral contractions and increasing pyloric tone. This pharmacodynamic effect, while intended to improve glycemic control, can lead to prolonged gastric retention. In susceptible individuals, this may progress to symptomatic gastroparesis, especially if the drug is continued despite persistent symptoms.
What are the symptoms of gastroparesis associated with Ozempic?
Symptoms of gastroparesis include nausea, vomiting, early satiety, bloating, and abdominal pain. These symptoms overlap with the common gastrointestinal adverse reactions reported in Ozempic clinical trials, such as nausea (15.8-20.3%), vomiting (5.0-9.2%), abdominal pain (5.7-7.3%), and constipation (3.1-5.0%). Persistent symptoms should prompt evaluation for gastroparesis.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.